| Patrick Dolan, | |
|
148 East Ave Ste 3a, Norwalk, CT 06851-5726 | |
| (203) 852-4934 | |
| Not Available |
| Full Name | Patrick Dolan |
|---|---|
| Gender | Male |
| Speciality | General Surgery |
| Experience | 10 Years |
| Location | 148 East Ave Ste 3a, Norwalk, Connecticut |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1144648767 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208600000X | Surgery | 289271-01 (New York) | Secondary |
| 208600000X | Surgery | 75125 (Connecticut) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Norwalk Hospital | Norwalk, CT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Nuvance Health Medical Practice Ct Inc | 4789597691 | 648 |
News Archive
NIBIB-funded researchers at the Massachusetts General Hospital have developed a smartphone-based device that can reliably carry out molecular diagnoses in under an hour for approximately two dollars per patient. The device could enable point-of-care cancer diagnostics in low- to middle-income or remote areas, which often have high rates of mortality from cancer due to missed opportunities for treatment.
Hereditary colorectal cancers, caused by inherited gene mutations, are relatively rare for most patients. However, researchers at The University of Texas MD Anderson Cancer Center have discovered a particularly high prevalence of hereditary cancers among those diagnosed with the disease before the age of 35. They suggest that these patients should undergo genetic counseling to determine if their families may be at an elevated risk.
Despite the common clinical practice among surgeons to discontinue their patients' anti-platelet therapy prior to surgery, a recent study of patients undergoing carotid endarterectomy (CEA) indicated that this practice may be unnecessary.
StemCells, Inc. (NASDAQ:STEM) today announced organizational initiatives focused on growing its specialty SC Proven® cell culture product business and advancing the development and commercialization of its central nervous system (CNS) cell-based assay platforms for use in drug screening and drug development. These initiatives reflect the Company's ongoing integration of the operations acquired from Stem Cell Sciences (SCS) Plc in April, and include new personnel appointments and a realignment of activities within the Company's Cambridge, UK and Palo Alto, California locations.
› Verified 6 days ago
| Entity Name | Nuvance Health Medical Practice Ct Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1407898117 PECOS PAC ID: 4789597691 Enrollment ID: O20031205000130 |
News Archive
NIBIB-funded researchers at the Massachusetts General Hospital have developed a smartphone-based device that can reliably carry out molecular diagnoses in under an hour for approximately two dollars per patient. The device could enable point-of-care cancer diagnostics in low- to middle-income or remote areas, which often have high rates of mortality from cancer due to missed opportunities for treatment.
Hereditary colorectal cancers, caused by inherited gene mutations, are relatively rare for most patients. However, researchers at The University of Texas MD Anderson Cancer Center have discovered a particularly high prevalence of hereditary cancers among those diagnosed with the disease before the age of 35. They suggest that these patients should undergo genetic counseling to determine if their families may be at an elevated risk.
Despite the common clinical practice among surgeons to discontinue their patients' anti-platelet therapy prior to surgery, a recent study of patients undergoing carotid endarterectomy (CEA) indicated that this practice may be unnecessary.
StemCells, Inc. (NASDAQ:STEM) today announced organizational initiatives focused on growing its specialty SC Proven® cell culture product business and advancing the development and commercialization of its central nervous system (CNS) cell-based assay platforms for use in drug screening and drug development. These initiatives reflect the Company's ongoing integration of the operations acquired from Stem Cell Sciences (SCS) Plc in April, and include new personnel appointments and a realignment of activities within the Company's Cambridge, UK and Palo Alto, California locations.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Patrick Dolan, 148 East Ave Ste 3a, Norwalk, CT 06851-5726 Ph: () - | Patrick Dolan, 148 East Ave Ste 3a, Norwalk, CT 06851-5726 Ph: (203) 852-4934 |
News Archive
NIBIB-funded researchers at the Massachusetts General Hospital have developed a smartphone-based device that can reliably carry out molecular diagnoses in under an hour for approximately two dollars per patient. The device could enable point-of-care cancer diagnostics in low- to middle-income or remote areas, which often have high rates of mortality from cancer due to missed opportunities for treatment.
Hereditary colorectal cancers, caused by inherited gene mutations, are relatively rare for most patients. However, researchers at The University of Texas MD Anderson Cancer Center have discovered a particularly high prevalence of hereditary cancers among those diagnosed with the disease before the age of 35. They suggest that these patients should undergo genetic counseling to determine if their families may be at an elevated risk.
Despite the common clinical practice among surgeons to discontinue their patients' anti-platelet therapy prior to surgery, a recent study of patients undergoing carotid endarterectomy (CEA) indicated that this practice may be unnecessary.
StemCells, Inc. (NASDAQ:STEM) today announced organizational initiatives focused on growing its specialty SC Proven® cell culture product business and advancing the development and commercialization of its central nervous system (CNS) cell-based assay platforms for use in drug screening and drug development. These initiatives reflect the Company's ongoing integration of the operations acquired from Stem Cell Sciences (SCS) Plc in April, and include new personnel appointments and a realignment of activities within the Company's Cambridge, UK and Palo Alto, California locations.
› Verified 6 days ago
Dr. Gregory Eckenrode, M.D. Surgery Medicare: Medicare Enrolled Practice Location: 30 Stevens St Ste D, Norwalk, CT 06850 Phone: 203-852-2406 Fax: 203-899-5281 | |
Jill Bianca Watras, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 34 Maple St, Norwalk, CT 06850 Phone: 703-867-6793 | |
Dr. Mandy Sher Greenberg, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 761 Main Ave, Suite 203, Norwalk, CT 06851 Phone: 203-846-6012 Fax: 203-846-6014 | |
Alexandria Marie Gallagher, DO Surgery Medicare: Medicare Enrolled Practice Location: 34 Maple St, Norwalk, CT 06850 Phone: 203-852-2000 | |
Klaus Thaler, MD Surgery Medicare: Not Enrolled in Medicare Practice Location: 30 Stevens St, Norwalk, CT 06850 Phone: 203-852-3379 Fax: 203-855-3878 | |
Dr. Peter Anthony Ingraldi, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 148 East Ave Ste 3a, Norwalk, CT 06851 Phone: 203-899-0744 Fax: 203-899-0761 |